Recombinant zoster vaccine vs placebo
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
- RR 6.89 [6.37, 7.45]2 studies · 9769 participantsModerate